|
Gene: GRSF1 |
Gene summary for GRSF1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | GRSF1 | Gene ID | 2926 |
Gene name | G-rich RNA sequence binding factor 1 | |
Gene Alias | GRSF1 | |
Cytomap | 4q13.3 | |
Gene Type | protein-coding | GO ID | GO:0000957 | UniProtAcc | A0A024RD99 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2926 | GRSF1 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.27e-09 | 4.76e-01 | -0.1954 |
2926 | GRSF1 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.67e-08 | 5.46e-01 | 0.294 |
2926 | GRSF1 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.38e-03 | 4.12e-01 | 0.3859 |
2926 | GRSF1 | A002-C-010 | Human | Colorectum | FAP | 5.75e-03 | -1.00e-01 | 0.242 |
2926 | GRSF1 | A015-C-203 | Human | Colorectum | FAP | 1.03e-11 | -1.47e-01 | -0.1294 |
2926 | GRSF1 | A002-C-201 | Human | Colorectum | FAP | 2.98e-03 | -1.30e-01 | 0.0324 |
2926 | GRSF1 | A001-C-108 | Human | Colorectum | FAP | 9.91e-05 | -7.65e-02 | -0.0272 |
2926 | GRSF1 | A002-C-205 | Human | Colorectum | FAP | 7.21e-06 | -7.53e-02 | -0.1236 |
2926 | GRSF1 | A015-C-006 | Human | Colorectum | FAP | 9.05e-05 | -1.18e-01 | -0.0994 |
2926 | GRSF1 | A015-C-106 | Human | Colorectum | FAP | 4.19e-05 | -1.60e-01 | -0.0511 |
2926 | GRSF1 | A002-C-114 | Human | Colorectum | FAP | 1.44e-04 | -9.74e-02 | -0.1561 |
2926 | GRSF1 | A015-C-104 | Human | Colorectum | FAP | 1.81e-13 | -1.33e-01 | -0.1899 |
2926 | GRSF1 | A001-C-014 | Human | Colorectum | FAP | 3.88e-03 | -6.35e-02 | 0.0135 |
2926 | GRSF1 | A002-C-016 | Human | Colorectum | FAP | 1.83e-08 | -1.02e-01 | 0.0521 |
2926 | GRSF1 | A015-C-002 | Human | Colorectum | FAP | 2.38e-02 | -1.60e-02 | -0.0763 |
2926 | GRSF1 | A001-C-203 | Human | Colorectum | FAP | 4.29e-04 | -1.10e-01 | -0.0481 |
2926 | GRSF1 | A002-C-116 | Human | Colorectum | FAP | 1.59e-13 | -1.30e-01 | -0.0452 |
2926 | GRSF1 | A014-C-008 | Human | Colorectum | FAP | 5.48e-03 | -2.07e-01 | -0.191 |
2926 | GRSF1 | A018-E-020 | Human | Colorectum | FAP | 5.97e-04 | -1.04e-01 | -0.2034 |
2926 | GRSF1 | F034 | Human | Colorectum | FAP | 5.89e-09 | -1.43e-01 | -0.0665 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00194395 | Colorectum | CRC | aromatic compound catabolic process | 77/2078 | 467/18723 | 2.42e-04 | 4.00e-03 | 77 |
GO:19013615 | Colorectum | CRC | organic cyclic compound catabolic process | 80/2078 | 495/18723 | 3.52e-04 | 5.34e-03 | 80 |
GO:00099521 | Colorectum | CRC | anterior/posterior pattern specification | 36/2078 | 201/18723 | 2.56e-03 | 2.40e-02 | 36 |
GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
GO:0043484111 | Esophagus | ESCC | regulation of RNA splicing | 116/8552 | 148/18723 | 3.18e-16 | 2.38e-14 | 116 |
GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
GO:00080333 | Esophagus | ESCC | tRNA processing | 92/8552 | 127/18723 | 7.83e-10 | 1.93e-08 | 92 |
GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
GO:00163316 | Esophagus | ESCC | morphogenesis of embryonic epithelium | 98/8552 | 147/18723 | 2.12e-07 | 3.27e-06 | 98 |
GO:00009592 | Esophagus | ESCC | mitochondrial RNA metabolic process | 39/8552 | 49/18723 | 1.20e-06 | 1.49e-05 | 39 |
GO:003112412 | Esophagus | ESCC | mRNA 3'-end processing | 47/8552 | 62/18723 | 1.29e-06 | 1.58e-05 | 47 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GRSF1 | SNV | Missense_Mutation | rs779804453 | c.1229N>C | p.Phe410Ser | p.F410S | Q12849 | protein_coding | tolerated(0.07) | probably_damaging(0.965) | TCGA-A2-A0YE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
GRSF1 | SNV | Missense_Mutation | novel | c.1224N>C | p.Leu408Phe | p.L408F | Q12849 | protein_coding | tolerated(0.28) | probably_damaging(0.998) | TCGA-A8-A09V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
GRSF1 | SNV | Missense_Mutation | rs779804453 | c.1229N>C | p.Phe410Ser | p.F410S | Q12849 | protein_coding | tolerated(0.07) | probably_damaging(0.965) | TCGA-EW-A1PH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
GRSF1 | deletion | Frame_Shift_Del | novel | c.904delN | p.Met302TrpfsTer7 | p.M302Wfs*7 | Q12849 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
GRSF1 | SNV | Missense_Mutation | novel | c.1388A>G | p.His463Arg | p.H463R | Q12849 | protein_coding | tolerated(0.13) | probably_damaging(0.929) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GRSF1 | SNV | Missense_Mutation | novel | c.478T>C | p.Ser160Pro | p.S160P | Q12849 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GRSF1 | SNV | Missense_Mutation | c.482N>A | p.Cys161Tyr | p.C161Y | Q12849 | protein_coding | deleterious(0.04) | possibly_damaging(0.9) | TCGA-C5-A7X3-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD | |
GRSF1 | SNV | Missense_Mutation | rs775900058 | c.892N>A | p.Glu298Lys | p.E298K | Q12849 | protein_coding | tolerated(0.36) | possibly_damaging(0.446) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GRSF1 | SNV | Missense_Mutation | rs368531595 | c.641N>A | p.Arg214His | p.R214H | Q12849 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GRSF1 | SNV | Missense_Mutation | c.1040N>T | p.Ala347Val | p.A347V | Q12849 | protein_coding | tolerated(0.12) | benign(0.049) | TCGA-CK-6751-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |